We are seeking strategic partners and investors to support the redevelopment of our preclinical proof of concept for Fraisinib, a highly promising small molecule that modulates GARS1 activity and Ap4A signaling. The project aims to align with EMA and FDA guidelines for future IND submission.
Fraisinib is a rationally designed small molecule that selectively targets glycyl-tRNA synthetase (GARS1), disrupting non-canonical pathways involved in tumor immune evasion and resistance. Preclinical studies demonstrate that Fraisinib modulates the levels of Ap4A, a metabolite implicated in immune regulation and purinergic signaling. This results in a significant reshaping of the tumor microenvironment (TME), reduction of pro-inflammatory mediators, and downregulation of different purinergic receptor activity, among which P2X4—highlighting its unique immunomodulatory and anti-angiogenic properties. Initial in vitro and in vivo data in non-small cell lung cancer models confirm Fraisinib’s capacity to boost apoptotic signaling and suppress tumor progression. Furthermore, in vivo studies have demonstrated excellent tolerability of Fraisinib across over 100 mice, including both immunocompetent and immunocompromised models. No weight loss, behavioral changes, or signs of organ toxicity were observed, even at doses well above the effective range. This mechanism-driven safety profile makes Fraisinib an ideal candidate for combination regimens or long-term administration. Proteomic and miRNA profiling further supports its multifaceted mechanism of action and paves the way for biomarker-guided development.
Current Stage & Objectives:
The current formulation (IV, DMSO/PEG300/Tween20) has shown efficacy at 3.5 mg/kg, with an ideal antitumor dose at 7.5 mg/kg. We are now seeking financial and strategic support to redesign our preclinical PoC to comply with EMA/FDA regulatory standards, including:
Full ADME and PK/PD characterization
GLP-compliant in vivo efficacy and safety studies
Regulatory toxicology planning
Preparation for IND-enabling studies
Collaboration Sought:
We are open to partnerships with biotech investors, pharma companies, and translational research consortia. Investment will drive a refined preclinical validation and allow us to accelerate Fraisinib’s journey toward clinical translation.
Why Fraisinib?
Because it represents a new paradigm in immunometabolic reprogramming—targeting a previously untapped node with both mechanistic novelty and robust experimental validation.
Let’s shape the future of cancer therapy together.
Intellectual property status
Patent already applied for
Patent application number : PCT/IB2023/054699
Granted Patent
Patent number : EP3519414B1
Granted Patent
Patent number : WO2018/061045
Giam Pharma International is an emerging pharmaceutical company focused on the discovery and development of next-generation therapeutics in oncology and rare diseases.
We combine scientific excellence with strategic agility to accelerate the transition from laboratory innovation to clinical application. Our core expertise lies in target identification, small-molecule design, and translational research, with a strong commitment to delivering high-impact treatments for patients with unmet medical needs.
Giam Pharma operates at the intersection of academic research and biotech entrepreneurship. We collaborate with leading research institutions, CROs, and strategic partners to drive preclinical validation, regulatory planning, and early-stage clinical development.
Our pipeline includes Fraisinib, a novel GARS1 inhibitor, currently undergoing full preclinical redevelopment prior to IND submission.
We are actively seeking strategic partnerships, licensing opportunities, and co-development agreements to accelerate our mission of advancing science into real-world therapies.
Create your free account to connect with Giacomo Drago and thousands of other innovative organizations and professionals worldwide
Send a request for information
to Giacomo
Technology Offers on Innoget are directly posted
and managed by its members as well as evaluation of requests for information. Innoget is the trusted open innovation and science network aimed at directly connect industry needs with professionals online.
Need help requesting additional information or have questions regarding this Technology Offer?
Contact Innoget support
